Nanovibronix (NASDAQ:FEED) Insider Sells $144,900.00 in Stock

Nanovibronix, Inc. (NASDAQ:FEED) insider Christian Michael Glibert sold 210,000 shares of the stock in a transaction dated Monday, June 22nd. The stock was sold at an average price of $0.69, for a total transaction of $144,900.00. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Nanovibronix Price Performance

Shares of FEED stock opened at $0.62 on Thursday. The firm has a market cap of $3.76 million, a PE ratio of -0.07 and a beta of 1.51. Nanovibronix, Inc. has a 52-week low of $0.61 and a 52-week high of $17.40. The firm has a 50-day moving average of $1.05.

Nanovibronix (NASDAQ:FEED) last posted its quarterly earnings data on Monday, May 18th. The company reported ($6.88) EPS for the quarter. Nanovibronix had a negative net margin of 923.20% and a negative return on equity of 54.25%. The company had revenue of $0.65 million for the quarter.

Wall Street Analysts Forecast Growth

FEED has been the topic of a number of analyst reports. Wall Street Zen upgraded shares of Nanovibronix from a “strong sell” rating to a “sell” rating in a research report on Tuesday, April 28th. Weiss Ratings restated a “sell (e+)” rating on shares of Nanovibronix in a research report on Friday, April 24th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Nanovibronix has a consensus rating of “Sell”.

Nanovibronix Company Profile

Nanovibronix (NASDAQ: FEED) is a medical device company focused on the development and commercialization of non?invasive therapeutic ultrasound technologies for clinical and consumer healthcare applications. The company’s product portfolio centers on wearable ultrasound devices designed to deliver low?intensity acoustic energy to soft tissue with the objective of promoting wound healing and reducing pain. Nanovibronix positions its technology as an alternative or adjunct to conventional wound?care and analgesic therapies, aiming to address chronic and acute conditions that are managed in both outpatient and home settings.

The company concentrates its commercial efforts on supplying hospitals, wound?care clinics, long?term care facilities and patients requiring home?based therapies.